BCR and chronic myelogenous leukemia, BCR-ABL1 positive: miR-451, miR-203 and miR-320a are described as downregulated in CML, since they directly target ABL and BCR-ABL1 acting as tumour suppressors, by reducing BCR-ABL oncoprotein expression12,17.